Lixisenatide (Lyxumia): new GLP-1 mimetic for type 2 diabetes

Lixisenatide is a new GLP-1 mimetic for use in type 2 diabetes with oral agents and/or insulin. In our New products review, Steve Chaplin presents the data relating to its efficacy and adverse events, and Dr Frank Joseph discusses its place in therapy.

Lixisenatide Lyxumia new GLP1 mimetic for type 2 diabetes

Add yours ↓
Web design and marketing agency Leamington Spa